Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 4/20 | 0.45 |
| ▸ | CPT2 | P23786 | 3/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3963782 | 0.97 | CPT1A (0.48) | CPT1ACPT2 | |
| SCHEMBL3961986 | 0.97 | CPT1A (0.48) | CPT1ACPT2 | |
| SCHEMBL2895611 | 0.85 | CPT1A (0.47) | CPT1ACPT2GRM5 | |
| SCHEMBL8233479 | 0.85 | CPT1A (0.45) | CPT1ACPT2 | |
| SCHEMBL5483440 | 0.82 | CPT1A (0.50) | CPT1ACPT2 | |
| SCHEMBL8220751 | 0.82 | CPT1A (0.48) | CPT1ACPT2 | |
| SCHEMBL8228386 | 0.82 | CPT1A (0.48) | CPT1ACPT2 | |
| SCHEMBL2893896 | 0.81 | CPT1A (0.42) | CPT1ACPT2GRM5CHRNB2CHRNA5 | |
| SCHEMBL2895923 | 0.81 | CPT1A (0.48) | CPT1ACPT2 | |
| SCHEMBL2895918 | 0.81 | CPT1A (0.48) | CPT1ACPT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027110-A2 | MGLUR5 MODULATORS III | Astra Zeneca AB (SE) | 2009-02-25 | — | — | EP | claimed |
| EP-2027120-A2 | MGLUR5 MODULATORS I | AstraZeneca AB (SE) | 2009-02-25 | — | — | EP | claimed |
| WO-2007130820-A2 | MGLUR5 MODULATORS I | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | claimed |
| WO-2007130822-A2 | MGLUR5 MODULATORS III | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | claimed |
| US-20070259926-A1 | mGluR5 modulators III | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | disclosed |
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | disclosed |
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | disclosed |
| US-20070259926-A1 | mGluR5 modulators III | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259926-A1 | mGluR5 modulators III | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259926-A1 | mGluR5 modulators III | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259862-A1 | MGluR5 modulators I | GRM5, GRM1, GRIK5 | CPT1A 1219/4885CPT2 1082/4885GRM5 1/4885 |
| US-20070259926-A1 | mGluR5 modulators III | GRM5, GRM3, GRIK5 | CPT1A 1746/4885CPT2 1267/4885GRM5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.